An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...

Reviews of the latest movies starring Henry Golding and Peter Sarsgaard. Read more at straitstimes.com. Read more at ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder ...

Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

Pfizer said today it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...